Agent or method for treating severe aphasia in cerebrovascular accident chronic stage
OwnerHideki Ohyamainventor
Life of this patent
Estimating the term…
Abstract
This relates to an agent or method for treating severe aphasia in cerebrovascular accident chronic stage, which comprises 2-oxo-1-pyrrolidineacetamide as an active ingredient.
Claims4
An agent for treating severe aphasia in cerebrovascular accident chronic stage, which comprises 2-oxo-1-pyrrolidineacetamide as an active ingredient.
A method for treating severe aphasia in cerebrovascular accident chronic stage, which comprises administering an effective amount of an agent for treating severe aphasia in cerebrovascular accident chronic stage, which comprises 2-oxo-1-pyrrolidineacetamide as an active ingredient, to a patient having severe aphasia in cerebrovascular accident chronic stage.
A method for treating severe aphasia, which comprises administering an agent comprising 2-oxo-1-pyrrolidineacetamide as an active ingredient at a dose of from 9 to 40 g/day for a long term of 2 months or more to a patient diagnosed as severe aphasia in cerebrovascular accident chronic stage and having no expectation of improvement in the symptoms even after a passage of 3 years or more of language rehabilitation period.
Use of 2-oxo-1-pyrrolidineacetamide for the manufacture of an agent for treating severe aphasia in cerebrovascular accident chronic stage.
Dependencies are inferred from the claim text.